These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20981590)

  • 1. [SRC kinases in tumor therapy].
    Dempke W; Zippel R
    Med Klin (Munich); 2010 Oct; 105(10):711-5. PubMed ID: 20981590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Src in solid tumors.
    Wheeler DL; Iida M; Dunn EF
    Oncologist; 2009 Jul; 14(7):667-78. PubMed ID: 19581523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of SRC inhibitors in solid tumor malignancies.
    Puls LN; Eadens M; Messersmith W
    Oncologist; 2011; 16(5):566-78. PubMed ID: 21521831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
    Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
    Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of Src in prostate cancer.
    Fizazi K
    Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
    Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
    Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on dual Src/Abl inhibitors.
    Musumeci F; Schenone S; Brullo C; Botta M
    Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
    Lee D; Gautschi O
    Clin Lung Cancer; 2006 May; 7(6):381-4. PubMed ID: 16800962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib: an anti-tumour agent via Src inhibition.
    Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
    Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src as a therapeutic target in men with prostate cancer and bone metastases.
    Saad F
    BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.
    Ahluwalia MS; de Groot J; Liu WM; Gladson CL
    Cancer Lett; 2010 Dec; 298(2):139-49. PubMed ID: 20947248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib in solid tumors.
    Kim LC; Rix U; Haura EB
    Expert Opin Investig Drugs; 2010 Mar; 19(3):415-25. PubMed ID: 20113198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
    Johnson FM; Saigal B; Tran H; Donato NJ
    Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src kinases as therapeutic targets for cancer.
    Kim LC; Song L; Haura EB
    Nat Rev Clin Oncol; 2009 Oct; 6(10):587-95. PubMed ID: 19787002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone targeted therapies: new agents].
    Barth C; Massard C; Vignot S
    Bull Cancer; 2013 Nov; 100(11):1215-21. PubMed ID: 24158596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
    Roseweir AK; Qayyum T; Lim Z; Hammond R; MacDonald AI; Fraser S; Oades GM; Aitchison M; Jones RJ; Edwards J
    BMC Cancer; 2016 Mar; 16():229. PubMed ID: 26984511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
    Wheeler DL; Iida M; Kruser TJ; Nechrebecki MM; Dunn EF; Armstrong EA; Huang S; Harari PM
    Cancer Biol Ther; 2009 Apr; 8(8):696-703. PubMed ID: 19276677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.